PLRX
What one share of Pliant Therapeutics holds
Pharmaceutical Preparations
We are a clinical-stage biopharmaceutical company focused on discovering and developing integrin-based therapeutics. Our lead program is focused on the development of treatments for solid tumors by inhibiting integrin-mediated activation of transforming growth factor-β (TGF-β).
Pliant Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.50 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$1.15 |
| Dividends | $0.00 |
| Cash and investments | $0.40 |
| Debt | $0.00 |
| Book value | $2.37 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | $35.14 | −$4.22 | $0.59 | −$2.29 | — | −$41.33 |
| 2020 | $1.96 | −$1.95 | $0.07 | −$1.82 | — | $7.96 |
| 2021 | $0.21 | −$2.71 | $0.05 | −$2.16 | $0.00 | $5.52 |
| 2022 | $0.23 | −$2.94 | $0.04 | −$2.29 | $0.00 | $6.40 |
| 2023 | $0.03 | −$2.75 | $0.02 | −$2.00 | $0.00 | $7.90 |
| 2024 | $0.00 | −$3.47 | $0.06 | −$2.63 | $0.00 | $5.00 |
| 2025 | $0.00 | −$2.43 | $0.01 | −$2.10 | $0.00 | $2.95 |